First-in-class approval of a tailored formulation for pediatric sickle cell disease patients

The European Medicines Agency (EMA) has approved Siklos (active ingredient: hydroxycarbamide) from Addmedica, a French company, for the treatment of sickle cell disease. Siklos works by inhibiting ribonucleotide reductase, thereby inducing the production of fetal hemoglobin (HbF). While generic hydroxyurea drugs already exist, there has been a lack of precise dosage formulations for pediatric patients, leading to challenges in clinical practice. This approval represents a significant advancement as it is the first to provide a double-scored tablet, easily divisible into 100mg and 1,000mg units, for patients aged two years and older. This will significantly reduce the risk of side effects and maximize the convenience of medication for pediatric patients, creating a better treatment environment.

Efficacy proven through large-scale clinical trials and real-world data

The approval of Siklos is based on clinical trials (Escort-HU) and real-world evidence conducted on pediatric and adult patients with sickle cell disease. Clinical results showed that Siklos significantly reduced the frequency of vaso-occlusive crises (VOC), the most life-threatening complication of sickle cell disease. It also significantly reduced the need for blood transfusions, greatly improving patients' quality of life. However, as a ribonucleotide reductase inhibitor, it carries warnings about side effects such as myelosuppression and carcinogenicity, requiring regular blood tests for monitoring. Regulatory authorities determined that the clinical benefits far outweigh these risks and granted final approval.

Overcoming the limitations of the generic market with the power of formulation patents

The global market for sickle cell disease treatments is estimated at approximately $3 billion to $4.7 billion annually and is showing steady growth. High-priced targeted therapies such as Endari (active ingredient: L-glutamine) from Emmaus Life Sciences and Adakveo (active ingredient: crizanlizumab) from Novartis are competing in the market. Recently, Casgevy, the first CRISPR gene therapy co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has also emerged, intensifying market competition. Amidst this, Siklos is increasing its market penetration by leveraging its affordable price and unique, tailored formulation for pediatric patients. It overcomes the limitations of generic drugs with patented formulation technology, maintaining a solid market share.

Expanding global reach through exclusive distribution partnerships

Addmedica has selected Medunik USA as its U.S. distribution partner for Siklos and entered into an exclusive sales partnership to expand its global reach. Due to the nature of the agreement between private companies, specific upfront payments or milestone amounts are not publicly disclosed. Medunik USA is rapidly expanding commercial success by accelerating the inclusion of Siklos in Medicaid programs in each state. Following the merger of Addmedica with Theravia and its subsequent acquisition by Norgine, a global pharmaceutical company, the global supply chain for Siklos is expected to be further strengthened. Based on a patient pool of 50,000 in Europe, it is expected to generate stable cash flow and play a significant role as a long-term cash cow.

Why it matters

The EMA approval of Siklos is a prime example of how Addmedica has demonstrated that it is possible to create high added value in the generic hydroxyurea market, not just through price competition, but through patents for pediatric, precise dosage formulations. This provides a solid basis for Siklos to secure a strong niche market in the global SCD market of $3 billion to $4.7 billion, even as existing SCD targeted therapies such as Emmaus' Endari and Novartis' Adakveo, and new gene therapies such as Vertex's Casgevy, enter the market. In the short term, immediate revenue generation is expected through the accelerated inclusion in Medicaid programs by its U.S. distribution partner, Medunik USA. In the medium to long term, it is analyzed that the merger of the developer, Addmedica, with Theravia and its subsequent acquisition by the global pharmaceutical company Norgine will lead to an increase in the corporate value of its rare disease portfolio. In particular, the approval based on data from the Escort-HU Phase 3 trial for patients aged two years and older provides an important benchmark for competing biotech companies to extend the life cycle of patented drugs through formulation differentiation.